leisure time -WSS

leisure time

author：explore 2025-10-02 14:03:18 - browse：76

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Medicare bonuses could stop drug shortages under Senate plan

WSS

Dog Aging Project founders on what lies ahead after losing funding

There's an unseen cost to disruptive road

To bolster infectious disease surveillance, genomics powerhouses team up

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

focus

leisure time

leisure time

Medical leaders decry Supreme Court decision on affirmative action

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Medicare Advantage overpayments discussion gets experts fired up

Peter Hotez and the public health issue of online harassment

Life science postdocs should get big pay hike, NIH panel says

Medicare proposal to cover medical devices draws a mixed reaction

Study suggests new cause of Down syndrome: cells linked to aging

Medical leaders decry Supreme Court decision on affirmative action

Allen Institute goes after foundational questions, CEO Costa says

knowledge

Study suggests new cause of Down syndrome: cells linked to aging

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Immunocompromised patients offer clues on chronic Covid

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Arena BioWorks launches in Cambridge to speed drug discovery

Medicare drug price lawsuits could be good politics for Biden

explore

Wikipedia

hotspot

knowledge